Abstract
Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
Current Pharmacogenomics and Personalized Medicine
Title: Pharmacogenomics of Open-Angle Glaucoma
Volume: 6 Issue: 2
Author(s): Stephen G. Schwartz, Juan A. Ayala-Haedo, Krishna S. Kishor and M. Elizabeth Fini
Affiliation:
Abstract: Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
Export Options
About this article
Cite this article as:
Schwartz G. Stephen, Ayala-Haedo A. Juan, Kishor S. Krishna and Fini Elizabeth M., Pharmacogenomics of Open-Angle Glaucoma, Current Pharmacogenomics and Personalized Medicine 2008; 6 (2) . https://dx.doi.org/10.2174/1875692110806020121
DOI https://dx.doi.org/10.2174/1875692110806020121 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology Diffusion of Macromolecule Through Retina After Experimental Branch Retinal Vein Occlusion and Estimate of Intraretinal Barrier
Current Drug Metabolism The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema
Current Pharmaceutical Design Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews The Hellp Syndrome: A Review
Current Women`s Health Reviews Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
Current Drug Safety Intravitreal Dexamethasone Implant <i>versus</i> Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial
Current Drug Delivery Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Ocular Complications of Drugs Used in Rheumatic Disease
Current Rheumatology Reviews Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study
Current Rheumatology Reviews